<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487160</url>
  </required_header>
  <id_info>
    <org_study_id>SBL-INI-02-13</org_study_id>
    <nct_id>NCT02487160</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens</brief_title>
  <official_title>Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lenstec Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lenstec Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the SBL-3 intraocular
      lens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety (adverse events) and performance (visual
      acuity, spectacle independence) of the SBL-3 intraocular lens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>photopic, distance corrected, monocular near visual acuity</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>presence or absence of adverse events</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>photopic, distance corrected, monocular intermediate visual acuity</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>photopic, best corrected, monocular distance visual acuity</measure>
    <time_frame>1 year following implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are independent of spectacles</measure>
    <time_frame>1 year following implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Cataracts</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>SBL-3 multifocal intraocular lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control monofocal intraocular lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SBL-3 multifocal intraocular lens</intervention_name>
    <description>The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
    <arm_group_label>SBL-3 multifocal intraocular lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control monofocal intraocular lens</intervention_name>
    <description>The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group</description>
    <arm_group_label>Control monofocal intraocular lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 22 years of age, of any race and either gender

          2. Operable, age related cataract grade in both eyes

          3. Patients who require an intraocular lens (IOL) power in the range of 15 D - 30 D only

          4. Able to comprehend and sign a statement of informed consent

          5. Calculated lens power within the available supply range

          6. Planned cataract removal by phacoemulsification

          7. Potential postoperative visual acuity of 0.2 Logarithm of the Minimum Angle of
             Resolution (logMAR) or better in both eyes

          8. In good general and ocular health

          9. Patients with preoperative astigmatism ≤1.0 D Note: Corneal incisions made to reduce
             astigmatism will not be allowed during the course of the study.

         10. Clear intraocular media other than cataract in study eyes

         11. Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR

         12. The subject must be able to undergo second eye surgery between 7 days and 30 days of
             the first eye surgery

         13. Able to competently complete testing

         14. Willing and able to attend study visits

        Exclusion Criteria:

          1. Previous intraocular surgery

          2. Preoperative photopic pupil size of &lt; 2.75 mm

          3. Previous corneal refractive surgery

          4. Any inflammation or edema (swelling) of the cornea

          5. Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or
             other retinal disorders ) that are predicted to cause future acuity losses to a level
             worse than 0.2 logMAR

          6. Subjects who may reasonably be expected to require a secondary surgical intervention
             at any time during the study (other than neodymium-doped yttrium aluminium garnet
             (nd:YAG) capsulotomy)

          7. Amblyopia

          8. Clinically significant ptosis

          9. Clinically severe corneal dystrophy (eg., epithelial, stromal, or endothelial
             dystrophy), keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or kerectasia

         10. Diabetic Retinopathy

         11. Extremely shallow anterior chamber, not due to swollen cataract

         12. Microphthalmia

         13. Previous retinal detachment

         14. Previous corneal transplant

         15. Severe dry eye

         16. Recurrent severe anterior or posterior segment inflammation of unknown etiology

         17. Systemic medications that may confound the outcome or increase the risk to the subject
             in the opinion of the Investigator [tamsulosin hydrochloride (Flomax) or other
             medications with similar side effects (floppy iris syndrome)]

         18. Rubella or traumatic cataract

         19. Iris neovascularization

         20. Glaucoma (medically controlled or uncontrolled)

         21. Aniridia

         22. Chronic severe uveitis

         23. Optic nerve atrophy

         24. Corneal decompensation

         25. Greater than 1.0 D of astigmatism

         26. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.)

         27. Pseudoexfoliation syndrome

         28. Iris atrophy

         29. Pupil abnormalities (e.g., corectopia)

         30. Aniseikonia

         31. An acute or chronic disease or illness that may confound the results of this
             investigation (e.g., immunocompromised, connective tissue disease, clinically
             significant atopic disease, diabetes, and any other such disease or illness)

         32. Pregnant, lactating, or planning to become pregnant during the course of the trial
             Note: Subjects who become pregnant during the study will not be discontinued; however,
             data may be excluded from the effectiveness analyses because pregnancy can alter
             refraction and visual acuity results.

         33. Participation in another clinical trial within 30 days of study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blake Harris</last_name>
    <role>Study Director</role>
    <affiliation>Lenstec Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blake Harris</last_name>
    <phone>727-571-2272</phone>
    <email>Bharris@Lenstec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jimmy Chacko</last_name>
    <phone>727-571-2272</phone>
    <email>jchacko@lenstec.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Center South</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Handal</last_name>
      <phone>334-718-6724</phone>
      <email>ignaciohandal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sebastian B Heersink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shepard Eye Center</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Thornton</last_name>
      <phone>805-925-2637</phone>
    </contact>
    <contact_backup>
      <last_name>Betty Figueroa</last_name>
      <phone>805-925-2637</phone>
    </contact_backup>
    <investigator>
      <last_name>Stephan Bylsma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cape Coral Eye Center</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Bellaire, 2028</last_name>
      <phone>239-542-2020</phone>
      <email>kathleen.bellaire@tysoneye.com</email>
    </contact>
    <investigator>
      <last_name>Farrell Tyson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Centers of Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Wilson</last_name>
      <phone>888-393-2455</phone>
      <email>fdastudies@ecof.com</email>
    </contact>
    <investigator>
      <last_name>David C Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newsom Eye &amp; Laser Center</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leesa Skipper</last_name>
      <phone>863-385-1544</phone>
      <email>l.skipper@newsomeye.net</email>
    </contact>
    <investigator>
      <last_name>Hunter Newsom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Eye Centers</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Erickson</last_name>
      <phone>320-235-2020</phone>
      <email>Info@fischerlaser.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Center of Central PA</name>
      <address>
        <city>Allenwood</city>
        <state>Pennsylvania</state>
        <zip>17810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Mace</last_name>
      <phone>570-538-6002</phone>
      <email>lmace@eyecenterofpa.com</email>
    </contact>
    <investigator>
      <last_name>Scott Hartzell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Myers</last_name>
      <phone>570-714-5910</phone>
      <email>pmyers@icarespecialists.com</email>
    </contact>
    <investigator>
      <last_name>Harvey J Reiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Eyecare Physicians</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Sandoval, MD</last_name>
      <phone>843-881-3937</phone>
      <email>Helga.Sandoval@carolinaeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Kerry Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loden Vision Center</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Lamberth</last_name>
      <phone>615-859-3937</phone>
      <email>studies@lodenvision.com</email>
    </contact>
    <investigator>
      <last_name>James Loden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kleiman/Evangelista Eye Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Orlofski</last_name>
      <phone>817-784-0222</phone>
      <email>morlofski@keec.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Evangelista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Whitsett Vision Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiran Narrow</last_name>
      <phone>713-365-9099</phone>
      <email>s.narrow@doctorwhitsett.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Whitsett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Forcht</last_name>
      <phone>801-263-5745</phone>
      <email>nforcht@theeyeinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Robert Cionni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

